Integrin αVβ3 Function Influences Citalopram Immobility Behavior in the Tail Suspension Test.
TST
antidepressant
citalopram
integrin
mouse model
signaling network
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
10
2018
accepted:
23
01
2019
entrez:
22
2
2019
pubmed:
23
2
2019
medline:
23
2
2019
Statut:
epublish
Résumé
Human studies first identified genetic and expression interactions between integrin β3 and serotonin (5-HT) transporter (SERT) genes. This association has been further strengthened by our discovery that integrin β3-containing receptors (αvβ3) physically interact with, and thereby define, a subpopulation of SERTs that may represent the main target of selective serotonin reuptake inhibitors (SSRIs). In this study, we examine how integrin αvβ3 function influences the behavioral response to the highly SSRI citalopram in the tail suspension test. Mice bearing a conditional deletion of the integrin β3 gene in neurons, or those expressing a constitutively active αvβ3 receptor, have decreased sensitivity to citalopram, when compared to wild-type littermates. To identify potential signaling pathways downstream of integrin αvβ3 that could be altered in these mouse lines, and consequently influence citalopram response
Identifiants
pubmed: 30787865
doi: 10.3389/fnins.2019.00070
pmc: PMC6372549
doi:
Types de publication
Journal Article
Langues
eng
Pagination
70Subventions
Organisme : NIMH NIH HHS
ID : R01 MH090256
Pays : United States
Références
Nat Genet. 1999 Sep;23(1):99-103
pubmed: 10471508
Neuron. 2001 Oct 11;32(1):63-77
pubmed: 11604139
Cell. 2003 Aug 22;114(4):469-82
pubmed: 12941275
Neuron. 2003 Oct 30;40(3):501-14
pubmed: 14642275
Cell Cycle. 2004 Feb;3(2):108-10
pubmed: 14712065
Nat Neurosci. 2004 Oct;7(10):1059-69
pubmed: 15378065
Proteomics. 2005 Jun;5(9):2412-6
pubmed: 15880767
Neurosci Biobehav Rev. 2005;29(4-5):571-625
pubmed: 15890404
Psychopharmacology (Berl). 2005 Dec;183(2):257-64
pubmed: 16220334
Neuropsychopharmacology. 2006 Nov;31(11):2433-42
pubmed: 16554742
J Clin Invest. 2008 Apr;118(4):1544-52
pubmed: 18317590
BMC Neurosci. 2008 Dec 10;9 Suppl 3:S5
pubmed: 19091002
FASEB J. 2010 Apr;24(4):1117-27
pubmed: 19933310
Pharmacogenomics J. 2011 Apr;11(2):138-45
pubmed: 20212518
J Neurosci. 2010 Jun 2;30(22):7652-63
pubmed: 20519540
Curr Protoc Neurosci. 2011 Apr;Chapter 8:Unit 8.10A
pubmed: 21462162
Int J Neuropsychopharmacol. 2012 Jul;15(6):781-93
pubmed: 21682943
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):159-67
pubmed: 22449479
Development. 2012 Sep;139(17):3200-10
pubmed: 22872087
Pharmacol Biochem Behav. 2012 Dec;103(2):181-6
pubmed: 22960128
Neuroscience. 2013 Oct 22;251:33-50
pubmed: 23036622
Int J Neuropsychopharmacol. 2013 Apr;16(3):701-11
pubmed: 23237009
J Vis Exp. 2013 Apr 08;(74):null
pubmed: 23608783
Am J Med Genet B Neuropsychiatr Genet. 2013 Sep;162B(6):487-520
pubmed: 23852853
Neurochem Int. 2014 Jul;73:122-6
pubmed: 24083985
Mol Pharmacol. 2014 Jun;85(6):921-31
pubmed: 24695082
Neurosci Lett. 2014 Sep 19;580:163-8
pubmed: 25116759
Neuropsychopharmacology. 2015 Jul;40(8):2015-24
pubmed: 25684064
Pharmacogenomics. 2015;16(7):689-701
pubmed: 25943212
Transl Psychiatry. 2016 May 31;6(5):e827
pubmed: 27244236
Pharmacogenomics J. 2018 Jan;18(1):144-152
pubmed: 27752142
J Neurosci. 2017 Nov 15;37(46):11271-11284
pubmed: 29038237
Pharmacogenomics J. 2018 May 22;18(3):413-421
pubmed: 29160301
Front Mol Neurosci. 2017 Nov 02;10:355
pubmed: 29163031
J Mol Neurosci. 2018 Jan;64(1):102-110
pubmed: 29209901
Mol Psychiatry. 2018 Jul 23;:null
pubmed: 30038233
J Affect Disord. 2018 Dec 1;241:484-491
pubmed: 30149336